Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 272

Similar articles for PubMed (Select 7513599)

1.

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

Kerwin RW.

Br J Psychiatry. 1994 Feb;164(2):141-8. Review. No abstract available.

PMID:
7513599
2.

Pharmacotherapy of schizophrenia: a review.

Sigmundson HK.

Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S70-5. Review.

PMID:
7533053
3.

Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.

Keegan D.

Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S46-52. Review.

PMID:
7533051
4.
5.

Pathophysiology and treatment of negative symptoms.

Villeneuve A.

Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S53-8. Review.

PMID:
7533052
6.

Adverse reaction reporting and new antipsychotics.

Kerwin R.

Lancet. 1993 Dec 11;342(8885):1440. No abstract available.

PMID:
7504153
7.

Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.

Czobor P, Volavka J.

J Clin Psychopharmacol. 1993 Oct;13(5):332-42.

PMID:
7693770
8.

Antipsychotic medication in the treatment of schizophrenia.

Kane JM.

Isr J Psychiatry Relat Sci. 1995;32(1):30-7. Review.

PMID:
7542642
9.

New antipsychotic medications: do research results relate to clinical practice?

MacEwan GW.

Can J Psychiatry. 1993 Sep;38 Suppl 3:S75-9. Review.

PMID:
7504572
10.

Novel neuroleptics in schizophrenia: theory and clinical relevance.

Remington GJ.

Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S43-5. No abstract available.

PMID:
7533050
11.

Ethical issues in drug selection for schizophrenia.

Jeffries JJ.

Can J Psychiatry. 1993 Sep;38 Suppl 3:S70-4. Review.

PMID:
7504571
12.

Pharmacological profile of risperidone.

Ereshefsky L, Lacombe S.

Can J Psychiatry. 1993 Sep;38 Suppl 3:S80-8. Review.

PMID:
7504573
13.

[New psychopharmacologic alternatives in treatment of schizophrenia].

Bryois C.

Schweiz Arch Neurol Psychiatr. 1994;145(6):19-24. Review. French.

PMID:
7533941
14.

Conventional versus novel antipsychotics: changing concepts and clinical implications.

Remington G, Chong SA.

J Psychiatry Neurosci. 1999 Nov;24(5):431-41. Review.

15.

Schizophrenia and severe tardive dyskinesia responsive to risperidone.

Kopala LC, Honer WG.

J Clin Psychopharmacol. 1994 Dec;14(6):430-1. No abstract available.

PMID:
7533794
16.

[Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].

Guise S, Soubrouillard C, Blin O.

Encephale. 1997 Apr;23 Spec No 2:10-6. Review. French.

PMID:
9273300
17.

Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.

Chouinard G, Vainer JL, BĂ©langer MC, Turnier L, Beaudry P, Roy JY, Miller R.

Prog Neuropsychopharmacol Biol Psychiatry. 1994 Nov;18(7):1129-41.

PMID:
7531355
18.

Serotonin receptor responsivity in schizophrenia.

Kahn RS, Davidson M.

Int Clin Psychopharmacol. 1993 Nov;8 Suppl 2:47-51. Review. No abstract available.

PMID:
7911140
19.

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia.

Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K.

J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):45S-51S.

PMID:
7537287
20.

Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.

Busatto GF, Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Kerwin RW.

Psychopharmacology (Berl). 1995 Jan;117(1):55-61.

PMID:
7536945
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk